Hubro Therapeutics is pleased to announce that NOK 41,1 mill has been raised in a private placement.
The funds will be used to continue the company’s development of lead candidate vaccine FMPV-1, adjuvant GM-CSF and companion diagnostics,
as well as preparing for initiation of the phase 2 study with FMPV-1/GM-CSF in MSI-colorectal cancer.